<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01580397</url>
  </required_header>
  <id_info>
    <org_study_id>INNO-206-P2-PDA-01</org_study_id>
    <nct_id>NCT01580397</nct_id>
  </id_info>
  <brief_title>Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer</brief_title>
  <official_title>A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytRx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with metastatic, locally advanced, or unresectable pancreatic ductal carcinomas&#xD;
      (PDA) who have failed prior chemotherapy with gemcitabine regimens have an extremely poor&#xD;
      prognosis with progression-free survival of around 13 weeks and median overall survival of&#xD;
      approximately 20 weeks after second line chemotherapy. Recent studies suggest that albumin&#xD;
      may be preferentially concentrated in pancreatic cancers that appear to be starved for this&#xD;
      protein. Thus, any molecule attached to albumin would also collect inside the tumor. Based on&#xD;
      its postulated mechanism of action, INNO-206 may improve the activity of doxorubicin without&#xD;
      increasing its toxicity, as has been demonstrated in animal studies, and induce enhanced&#xD;
      anti-tumor efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Approximately 15 months from randomization.</time_frame>
    <description>Objective response rate is defined as Complete Responders + Partial Responders per RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>After all subjects have been on study for 4 months.</time_frame>
    <description>Disease control rate is Complete Responders + Partial Responders + Stable Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From the date of randomization until the date of first documented progression assessed up to 20 months.</time_frame>
    <description>A &gt;=20% increase in the sum of the LD of target lesions from the smallest sum of the LD recorded since the treatment started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments</measure>
    <time_frame>From randomization upto 15 months.</time_frame>
    <description>Adverse events, serious adverse events, vital signs, physical examinations, ECG, safety labs will be evaluated for overall toxicity of INNO-206 in this population.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>INNO-206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INNO-206</intervention_name>
    <description>INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.</description>
    <arm_group_label>INNO-206</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years of age; male or female.&#xD;
&#xD;
          -  Histologically or cytologically confirmed, locally advanced, unresectable, and/or&#xD;
             metastatic pancreatic ductal adenocarcinoma.&#xD;
&#xD;
          -  Cancer progression after treatment with one gemcitabine and one&#xD;
             fluoropyrimidine-containing chemotherapy regimen.&#xD;
&#xD;
          -  Capable of providing informed consent and complying with trial procedures.&#xD;
&#xD;
          -  ECOG performance status 0-1.&#xD;
&#xD;
          -  Life expectancy ≥ 8 weeks.&#xD;
&#xD;
          -  Measurable tumor lesions according to RECIST 1.1 criteria.&#xD;
&#xD;
          -  Women must not be able to become pregnant (eg post-menopausal for at least 1 year,&#xD;
             surgically sterile, or practicing adequate birth control methods) for the duration of&#xD;
             the study. (Adequate contraception includes: oral contraception, implanted&#xD;
             contraception, intrauterine device implanted for at least 3 months, or barrier method&#xD;
             in conjunction with spermicide.)&#xD;
&#xD;
          -  Women of child bearing potential must have a negative serum or urine pregnancy test at&#xD;
             the Screening Visit and be non-lactating.&#xD;
&#xD;
          -  Geographic accessibility to the site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior exposure to &gt; 3 cycles or 225 mg/m2 of doxorubicin or Doxil®.&#xD;
&#xD;
          -  Palliative surgery and/or radiation treatment less than 4 weeks prior to&#xD;
             Randomization.&#xD;
&#xD;
          -  Exposure to any investigational agent within 30 days of Randomization.&#xD;
&#xD;
          -  Evidence of central nervous system (CNS) metastasis (negative imaging study, if&#xD;
             clinically indicated, within 4 weeks of Screening Visit).&#xD;
&#xD;
          -  History of other malignancies (except cured basal cell carcinoma, superficial bladder&#xD;
             cancer or carcinoma in situ of the cervix) unless documented free of cancer for ≥ 5&#xD;
             years.&#xD;
&#xD;
          -  Laboratory values: Screening serum creatinine &gt; 1.5x upper limit of normal (ULN),&#xD;
             alanine aminotransferase (ALT) &gt; 3×ULN or &gt; 5×ULN if liver metastases are present,&#xD;
             total bilirubin &gt; 3×ULN, absolute neutrophil count &lt; 1,500/mm3, platelet concentration&#xD;
             &lt; 100,000/mm3, absolute lymphocyte count &lt; 1000/mm3, hematocrit level &lt; 27% for&#xD;
             females or &lt; 30% for males, or coagulation tests (prothrombin time [PT], partial&#xD;
             thromboplastin time [PTT], International Normalized Ratio [INR]) &gt; 1.5×ULN, serum&#xD;
             albumin ≤ 2.8 g/dL.&#xD;
&#xD;
          -  Clinically evident congestive heart failure &gt; class II of the New York Heart&#xD;
             Association (NYHA) guidelines.&#xD;
&#xD;
          -  Current, serious, clinically significant cardiac arrhythmias, defined as the existence&#xD;
             of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V.&#xD;
&#xD;
          -  History or signs of active coronary artery disease with or without angina pectoris.&#xD;
&#xD;
          -  Serious myocardial dysfunction ultrasound-determined, with absolute left ventricular&#xD;
             ejection fraction (LVEF) &lt; 45% of predicted.&#xD;
&#xD;
          -  History of HIV infection.&#xD;
&#xD;
          -  Active, clinically significant serious infection requiring treatment with antibiotics,&#xD;
             anti-virals or anti-fungals.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to Randomization.&#xD;
&#xD;
          -  Substance abuse or any condition that might interfere with the subject's participation&#xD;
             in the study or in the evaluation of the study results.&#xD;
&#xD;
          -  Any condition that is unstable and could jeopardize the subject's participation in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Von Hoff, M.D., F.A.C.P.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Genomics Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Levitt, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>CytRx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407-3799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin - Division of Neoplastic Diseases and Related Disorders</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2012</study_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>INNO-206</keyword>
  <keyword>Doxorubicin-EMCH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

